Esófago de Barrett. Neoplasias esofágicas

  1. Monteserín Ron, L. 1
  2. Domínguez Muñoz, J.E. 1
  1. 1 Servicio Aparato Digestivo, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, La Coruña, España
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Año de publicación: 2020

Título del ejemplar: Enfermedades del aparato digestivo (VII)Enfermedades del esófago

Serie: 13

Número: 7

Páginas: 392-400

Tipo: Artículo

DOI: 10.1016/J.MED.2020.05.004 DIALNET GOOGLE SCHOLAR

Otras publicaciones en: Medicine: Programa de Formación Médica Continuada Acreditado

Resumen

El esófago de Barrett representa la principal complicación de la enfermedad por reflujo gastroesofágico. Se trata de una condición adquirida, en la que se produce un reemplazo del epitelio escamoso esofágico distal presente en condiciones normales por un epitelio cilíndrico con presencia de metaplasia intestinal. Su importancia radica en su potencial para degenerar a adenocarcinoma esofágico, por lo que estos pacientes deben estar sujetos a un seguimiento endoscópico para la detección precoz de displasia o adenocarcinoma. El adenocarcinoma y el carcinoma epidermoide son las dos neoplasias esofágicas malignas más frecuentes, ambas asociadas al hábito tabáquico. El cáncer de esófago es el séptimo tumor más frecuente a nivel mundial, con una elevada tasa de mortalidad, ya que suele cursar asintomático en fases iniciales. Una correcta estadificación nos indicará el tratamiento más adecuado en cada caso.

Referencias bibliográficas

  • Zagari RM, Fuccio L, Wallander MA, Johansson S, Fiocca R, Casanova S, et al. Gastro-oesophageal reflux symptoms, oesophagitis and Barrett’s oesophagus in the general population: Loiano-Monghidoro study. Gut. 2008;57:1354-59.
  • Ronkainen J, Aro P, Storskrubb T, Johansson SE, Lind T, Bolling-Sternevald E, et al. Prevalence of Barrett’s esophagus in the general population: an endoscopic study. Gastroenterology. 2005;129:1825-31.
  • Juhasz A, Mittal SK, Lee TH, Deng C, Chak A, Lynch HT. Prevalence of Barrett’s Esophagus in first degree relatives of patients with esophageal adenocarcinoma. J Clin Gastroenterol. 2011;45:867-71.
  • Savarino E, De Bortoli N, De Cassan C, Della Coletta M, Bartolo O, Furnari M, et al. The natural history of gastro-esophageal reflux disease: a comprehensive review. Dis Esophagus. 2017;30:1-9.
  • Menges M, Muller M, Zeiz M. Increased acid and bile reflux in Barrett’s esophagus compared to reflux esophagitis, and effect of proton pump inhibitor therapy. Am J Gastroenterol. 2001;96:331-7.
  • Singh P, Taylor RH, Coli-Jones DG. Esophageal motor dysfunction and acid exposure in reflux esophagitis are more severe if Barrett’s metaplasia is present. Am J Gastroenterol. 1994;89:349-56.
  • Shaheen NJ, Falk GW, Iyer PG, Gerson LB. ACG Clinical Guideline: Diagnosis and Management of Barrett’s Esophagus. Am J Gastroenterol. 2016;111:30-50.
  • Anderson LA, Cantwell MM, Watson RG, Johnston BT, Murphy SJ, Fer-guson HR, et al. The association between alcohol and reflux esophagitis, Barrett’s esophagus, and esophageal adenocarcinoma. Gastroenterology. 2009;136:799-805.
  • Weusten B, Bisschops R, Coron E, Dinis-Ribeiro M, Dumon-ceau JM, Esteban JM, et al. Endoscopic management of Barrett’s esophagus: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement. Endoscopy 2017;49:191-8.
  • Fitzgerald RC, di Pietro M, Ragunath K, Ang Y, Kang JY, Watson P, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut. 2014;63:7-42.
  • ASGE Standards of Practice Committee, Evans JA, Early DS, Fukami N, Ben-Menachem T, Chandrasekhara V, et al. The role of endoscopy in Barrett’s esophagus and other premalignant conditions of the esophagus. Gastrointest Endosc. 2012;76:1087-94.
  • Hvid-Jensen F, Pedersen L, Drewes AM, Sørensen HT, Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med. 2011;365(15):1375-83.
  • Desai TK, Krishnan K, Samala N, Singh J, Cluley J, Perla S, et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett’s oesophagus: A meta-analysis. Gut. 2012;61(7):970-6.
  • Rastogi A, Puli S, El-Serag HB, Bansal A, Wani S, Sharma P. Incidence of esophageal adenocarcinoma in patients with Barrett’s esophagus and high-grade dysplasia: a meta-analysis. Gastrointest Endosc. 2008; 67(3): 394-8.
  • Haidry RJ, Magee C. Mistakes in the endoscopic diagnosis and management of Barrett’s oesophagus and how to avoid them. UEG Education 2018; 2018:12-14.
  • Gupta N, Gaddam S, Wani SB, Bansal A, Rastogi A, Sharma P. Longer inspection time is associated with increased detection of high-grade dysplasia and esophageal adenocarcinoma in Barrett’s esophagus. Gastrointest Endosc. 2012;76(3):531-8.
  • Visrodia K, Singh S, Krishnamoorthi R, Ahlquist DA, Wang KK, Iyer PG, et al. Magnitude of missed esophageal adenocarcinoma after Barrett’s esophagus diagnosis: a systematic review and meta-analysis. Gastroente-rology. 2016;150:599-607.e7.
  • Abrams JA, Kapel RC, Lindberg GM, Saboorian MH, Genta RM, Neu-gut AI, et al. Adherence to biopsy guidelines for Barrett’s esophagus surveillance in the community setting in the United States. Clin Gastroenterol Hepatol. 2009;7:736-42.
  • Sharma P, Dent J, Armstrong D, Bergman JJ, Gossner L, Hoshihara Y, et al. The development and validation of an endoscopic grading system for Barrett’s esophagus: The Prague C&M Criteria. Gastroenterology. 2006; 131(5):1392-9.
  • Sharma P, Hawes RH, Bansal A, Gupta N, Curvers W, Rastogi A, et al. Standard endoscopy with random biopsies vs NBI targeted biopsies in Barrett’s oesophagus: a prospective, international, randomised controlled trial. Gut. 2013;62:15-21.
  • Duits LC, Phoa KN, Curvers WL, Ten Kate FJ, Meijer GA, Seldenrijk CA, et al. Barrett’s oesophagus patients with low-grade dysplasia can be accurately risk-stratified after histological review by an expert pathology panel. Gut. 2015;64:700-6.
  • De la Coba C, Argüelles-Arias F, Martín-de-Argila C, Júdez J, Linares A, Ortega-Alonso A, et al. Efectos adversos de los inhibidores de la bomba de protones: revisión de evidencias y posiciona-miento de la Sociedad Española de Patología Digestiva. Rev Esp Enferm Dig. 2016;108:207-24.
  • Iyer PG, Kaul V. Barrett esophagus. Mayo Clin Proc. 2019;94(9):1888-901.
  • Standards of Practice Committee, Wani S, Qumseya B, Sultan S, Agrawal D, Chandrasekhara V, Harnke B, et al. Endoscopic eradication therapy for patients with Barrett’s esophagus-associated dysplasia and intramucosal cancer. Gastrointest Endosc. 2018;87(4):907-31.e9.
  • Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68:394-424.
  • Thrift AP. The epidemic of oesophageal carcinoma: Where are we now? Cancer Epidemiol. 2016;41:88.
  • Peter C, Enzinger MD, Robert J, Mayer MD. Esophageal cancer review article. N Engl J Med. 2003;349:2241-52.
  • Domper MJ, Ferrández A, Lanas A. Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries. World J Gastroenterol. 2015;21(26):7933-43.
  • Wheeler JB, Reed CE. Epidemiology of esophageal cancer. Surg Clin North Am. 2012;92:1077-87.
  • Rice TW, Patil DT, Blackstone EH. 8th edition AJCC/UICC staging of cancers of the esophagus and esophagogastric junction: application to clinical practice. Ann Cardiothorac Surg. 2017;6(2):119-30.
  • Martin-Richard M, Díaz Beveridge R, Arrazubi V, Alsina M, Galan Guz-mán M, Custodio AB, et al. SEOM Clinical Guideline for the diagnosis and treatment of esophageal cancer (2016). Clin Transl Oncol. 2016; 18(12):1179-86.
  • ASGE Standards of Practice Committee, Evans JA, Early DS, Chandras-khara V, Chathadi KV, Fanelli RD, Fisher DA, et al. The role of endoscopy in the assessment and treatment of esophageal cancer. Gastrointest Endosc. 2013;77(3):328-34.
  • Spaander MC, Baron TH, Siersema PD, Fuccio L, Schumacher B, Escor-sell À, et al. Esophageal stenting for benign and malignant disease: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. Endoscopy. 2016;48(10):939-48.
Fuente de los datos: Dialnet